Navigation Links
Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
Date:10/15/2008

rotein engineering technologies to create proprietary human protein pharmaceuticals with enhanced therapeutic properties for the treatment of hematopoietic and endocrine disorders, cancer and infectious diseases. For additional information about Bolder BioTechnology, Inc., please visit our web site at http://www.bolderbio.com.

Statements contained herein that are not historical facts are forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company. These factors include, but are not limited to: (1) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies, and commercialization; (2) the Company's ability to obtain required government approvals; (3) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (4) the Company's ability to develop and commercialize its products before its competitors.


'/>"/>
SOURCE Bolder BioTechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. New White Paper Details Strategies for Biotechnology Companies to Improve EH&S Compliance
3. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
4. Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
5. Luminex Corporation to Present at Biotechnology Industry Organization Investor Forum
6. An Uncommon Eye: Photography Exhibit by Biotechnology Executive at BHCC Gallery
7. Onyx Pharmaceuticals to Present at Biotechnology Industry Organization Investor Forum
8. Leading Biotechnology Company Grows with StayinFront CRM
9. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
10. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
11. Bionovo to Present at the Biotechnology Industry Organization (BIO) Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research ... on the current state of the global Propanol market with a focus on the ... Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem ...
(Date:7/30/2015)... , Inc. (NASDAQ: SNMX ), a leading company ... commercialize novel flavor ingredients for the food, beverage, and ... second quarter 2015. "Moving into the ... achieve our commercial and financial goals," stated John Poyhonen, ... our last quarterly earnings report, our two partners have ...
(Date:7/30/2015)...  Discovery Laboratories, Inc. (Nasdaq: DSCO ) ... $1.0M tranche under a previously awarded Phase II ... up to $3.0 million to support continued development ... potential medical countermeasure to mitigate acute and chronic/late-phase ... initial $1.0 million under this grant in October ...
(Date:7/29/2015)... July 30, 2015 Sanofi, ... publie ses résultats pour le premier semestre 2015. ... les résultats. Visionner l,interview vidéo et ... Au sommaire de l,interview :  ... Moteurs de croissance - Diabète ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... , SOUTH SAN FRANCISCO, Calif., Sept. 15 ... 320 evaluable events (patient deaths) have occurred in its pivotal Phase 3 ... in accordance with a Special Protocol Assessment (SPA) with the U.S. Food ... lung cancer (SCLC). , , "The ...
... , BASKING RIDGE, N.J., Sept. 15 ... antithrombotic aptamers with active control agents, announced today that ... BioPharm America Conference 2009 in San Francisco, CA at 3:15 ... will include an overview of the Company,s pipeline with emphasis ...
... KVISTGAARD, Denmark, September 15 Bavarian,Nordic A/S (OMX: BAVA) announced ... undisclosed EU country for the delivery of a small order for,IMVAMUNE(R). ... of,the contract is undisclosed. , This marks ... for the delivery of IMVAMUNE(R), and it demonstrates that there,exists a ...
Cached Biology Technology:Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target 2Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target 3Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target 4Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target 5Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009 2Bavarian Nordic Has Signed Contract With an EU Country for the Delivery of IMVAMUNE(R) 2
(Date:7/9/2015)... July 9, 2015  Unchained Labs just can,t ... acquisition of Avid Nano. Avid Nano designs, develops ... systems.    Also today, Unchained Labs ... easiest to use protein sizing system. The pUNk ... protein,s hydrodynamic size, size distribution, aggregation population and ...
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
(Date:7/8/2015)... 8, 2015  Trovagene, Inc. (NASDAQ: TROV ... announced the launch of a study that aims ... Monitoring℠ (PCM) technology for predicting response to treatment ... combination of the novel immunotherapy agents Yervoy® (ipilumumab), ... inhibitor. The 50-patient study will be led by ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... travel across a colony to actively seek males which ... local dominant males. These findings, published in this ... widespread in nature than previously believed and that such ... from the University of Cambridge and the British Antarctic ...
... in increasingly large areas. , The summer of 2006 ... records began in 1895, according to the National Climatic Data ... 40 percent of the country. , When Constance Brown ... struck by a major difference: people in Indiana don't think ...
... million research program at Iowa State University dedicated ... grant is part of ConocoPhillips' plan to create ... viable solutions to diversify America's energy sources. ... grant in 2007 to support Iowa State researchers, ...
Cached Biology News:Female Antarctic seals give cold shoulder to local males 2How trees manage water in arid environments 2How trees manage water in arid environments 3How trees manage water in arid environments 4ConocoPhillips establishes $22.5M biofuels research program at Iowa State 2ConocoPhillips establishes $22.5M biofuels research program at Iowa State 3
... Direct SPA Screening Assay, 5 ... that eliminate lengthy sample extraction procedures ... use).Range: 1.32-84.28 ng/ml (4-256 pmol/ml).Sensitivity: 0.65 ... 2-8 C. Category: Drug Screening & ...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Clone/PAD: ZMD.283. Immunogen: Fusion ... Specificity: Specific for ASIP/PAR-3 (atypical PKC ... This antigen is not related to ... Reactivity: Human Dog Xenopus (positive controls: ...
... synthase, cytoplasmic (C1-THF ... dehydrogenase (EC 1.5.1.5); ... 3.5.4.9); Formyltetrahydrofolate synthetase ... ...
Biology Products: